TMCnet News

Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at "IBD Innovate 2018" Conference Hosted by the Crohn's & Colitis Foundation
[November 13, 2018]

Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at "IBD Innovate 2018" Conference Hosted by the Crohn's & Colitis Foundation


BEVERLY, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is presenting a scientific poster—Brilacidin for Inflammatory Bowel Disease: A Novel, Non-Corticosteroid, Non-Biologic Drug Candidate in Clinical Development—at the inaugural “IBD Innovate 2018” conference, being held today in New York City and hosted by the Crohn’s & Colitis Foundation.

Participants include diverse stakeholders interested in scientific advances and innovative programs in Inflammatory Bowel Disease (IBD) toward accelerating the introduction of novel products to address unmet medical needs in the treatment of chronic bowel diseases. Additional conference details can be found on the Crohn’s & Colitis Foundation website by clicking here (pdf of full agenda).

Reflective of Brilacidin’s treatment potential in IBD given its unique immunomodulatory profile, the drug candidate has successfully been tested in a proof-of-concept study in distal colitis. Trial results showed that a majority of patients treated with Brilacidin achieved clinical remission, including mucosal healing as evidenced by endoscopic review, an increasingly important measure in establishing a drug’s efficacy. Plans include developing Brilacidin in an oral dosage form to treat more extensive forms of IBD, such as Ulcerative Colitis and Crohn’s Disease.

The scientific poster is now available on the Events and Presentations section f the Company website, linked to below.



http://www.ipharminc.com/new-events-and-presentations/2018/11/13/crohns-colitis-foundation-ibd-innovate-2018-conference

Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/


About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. Prurisol, an oral psoriasis drug candidate acting through immune modulation and PRINS reduction, has now completed a Phase 2b trial and is awaiting statistical analysis. More information is available on the Company website at www.IPharmInc.com.

Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals Inc.
Leo Ehrlich
[email protected]


[ Back To TMCnet.com's Homepage ]